Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DA-2902 and DA-2902-R in Healthy Adults
NCT07239453Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Nov 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-2902 in Infectious disease (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Curve from time zero to the last quantifiable concentration at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Started Nov 2025; status: completed.
02
Drugs
DA-2902
03
Conditions
Infectious disease
Beyond the preview
Go deeper on NCT07239453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239453.